Zacks: Analysts Expect Keryx Biopharmaceuticals (KERX) Will Announce Earnings of -$0.14 Per Share

Equities research analysts expect Keryx Biopharmaceuticals (NASDAQ:KERX) to announce ($0.14) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Keryx Biopharmaceuticals’ earnings, with estimates ranging from ($0.16) to ($0.11). Keryx Biopharmaceuticals posted earnings per share of ($0.21) in the same quarter last year, which suggests a positive year-over-year growth rate of 33.3%. The company is expected to report its next quarterly earnings results on Thursday, July 26th.

According to Zacks, analysts expect that Keryx Biopharmaceuticals will report full year earnings of ($0.55) per share for the current financial year, with EPS estimates ranging from ($0.61) to ($0.46). For the next financial year, analysts forecast that the business will report earnings of $0.01 per share, with EPS estimates ranging from ($0.18) to $0.37. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Keryx Biopharmaceuticals.

Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings data on Friday, May 11th. The biopharmaceutical company reported ($0.18) EPS for the quarter, meeting the consensus estimate of ($0.18). The company had revenue of $21.75 million during the quarter, compared to the consensus estimate of $21.80 million.

Several research firms recently commented on KERX. BidaskClub cut shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, June 30th. HC Wainwright began coverage on shares of Keryx Biopharmaceuticals in a research report on Thursday, June 28th. They issued a “buy” rating and a $9.00 price objective on the stock. ValuEngine raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 21st. Zacks Investment Research raised shares of Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research report on Tuesday, July 10th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $5.00 price target on shares of Keryx Biopharmaceuticals in a research report on Monday, June 25th. Six equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $6.70.

A number of large investors have recently modified their holdings of KERX. Millennium Management LLC bought a new stake in Keryx Biopharmaceuticals during the 1st quarter worth about $3,847,000. Summit Trail Advisors LLC lifted its position in Keryx Biopharmaceuticals by 355.3% during the 1st quarter. Summit Trail Advisors LLC now owns 333,803 shares of the biopharmaceutical company’s stock worth $334,000 after buying an additional 260,485 shares in the last quarter. First Trust Advisors LP bought a new stake in Keryx Biopharmaceuticals during the 4th quarter worth about $749,000. UBS Group AG lifted its position in Keryx Biopharmaceuticals by 126.0% during the 1st quarter. UBS Group AG now owns 231,934 shares of the biopharmaceutical company’s stock worth $949,000 after buying an additional 129,296 shares in the last quarter. Finally, BlackRock Inc. lifted its position in Keryx Biopharmaceuticals by 1.9% during the 4th quarter. BlackRock Inc. now owns 6,097,948 shares of the biopharmaceutical company’s stock worth $28,356,000 after buying an additional 112,381 shares in the last quarter. 61.61% of the stock is currently owned by hedge funds and other institutional investors.

KERX traded down $0.16 during trading on Monday, hitting $4.33. The company had a trading volume of 385,212 shares, compared to its average volume of 1,631,318. The stock has a market capitalization of $541.16 million, a P/E ratio of -4.92 and a beta of 2.65. Keryx Biopharmaceuticals has a one year low of $3.30 and a one year high of $8.07. The company has a current ratio of 2.66, a quick ratio of 1.87 and a debt-to-equity ratio of -3.96.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.

See Also: Book Value Per Share in Stock Trading

Get a free copy of the Zacks research report on Keryx Biopharmaceuticals (KERX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply